Allarity Therapeutics reports Q3 net loss $12.2M; cash $18.5M; Phase 2 stenoparib patients exceed one year on treatment

Allarity Therapeutics, Inc.

Net loss $12.2M vs $5.6M YoY; includes $9.7M non-cash intangible impairment charge.
Cash and equivalents $18.5M at Sept 30, 2024, up from $0.2M at Dec 31, 2023; runway into 2026.
Phase 2 stenoparib trial: two ovarian cancer patients exceeded one year on treatment.
Appointed Alexander Epshinsky as CFO; Jeremy Graff as President/Chief Development Officer; Jose Iglesias as Consultant CMO.
Regained NASDAQ compliance; European patent granted for stenoparib DRP companion diagnostic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.